SIREN : 491561197
MEDICASTE AMIENS is a French company founded 19 years ago, specialized in the sector Ingénierie, études techniques. Based in PARIS (75001), this company of category ETI shows in 2024 a revenue of 1.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-25
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 397 115 € | 1 419 009 € | 1 389 870 € | 1 381 166 € | 1 411 063 € | 1 428 882 € | 1 449 816 € | 1 455 104 € | 1 473 541 € |
| Net income | 4 297 € | 9 047 € | 6 196 € | 6 707 € | 8 020 € | 6 856 € | 7 394 € | 7 250 € | 3 224 € |
| EBITDA | 640 030 € | 677 346 € | 705 222 € | 736 124 € | 767 158 € | 792 217 € | 820 003 € | 843 156 € | 862 481 € |
| Net margin | 0.3% | 0.6% | 0.4% | 0.5% | 0.6% | 0.5% | 0.5% | 0.5% | 0.2% |
In 2024, MEDICASTE AMIENS achieves revenue of 1.4 M€. Activity remains stable over the period (CAGR: -0.7%). Slight decline of -2% vs 2023. After deducting consumption (0 €), gross margin stands at 1.4 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 640 k€, representing 45.8% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 4 k€, i.e. 0.3% of revenue. This profit can be retained or distributed to shareholders.
1 397 115 €
1 397 115 €
640 030 €
77 249 €
4 297 €
45.8%
The debt ratio (= Financial debt / Equity x 100) stands at 627%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 12%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 40.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
627.059%
12.482%
40.679%
2.1
8.1%
In 2024, the debt ratio of MEDICASTE AMIENS (627.06) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of MEDICASTE AMIENS (12.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of MEDICASTE AMIENS (2.10) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 486.19. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 11.2x. Operating income very largely covers interest expenses: high safety margin.
486.185
11.174
In 2024, the liquidity ratio of MEDICASTE AMIENS (486.19) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of MEDICASTE AMIENS (11.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 93 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 27 days. The gap of 66 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 99 days of revenue, i.e. 385 k€ to permanently finance. Notable WCR improvement over the period (-58%), freeing up cash.
384 626 €
93 j
27 j
0 j
99 j
Indicative estimate only : the number of comparable transactions in this sector is limited (40 transactions). This range of 151 579€ to 1 478 621€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 40 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MEDICASTE AMIENS with other companies in the same sector:
Voir toutes les statistiques du secteur Ingénierie, études techniques
The revenue of MEDICASTE AMIENS in 2024 is 1.4 M€.
Yes, MEDICASTE AMIENS generated a net profit of 4 k€ in 2024.
The headquarters of MEDICASTE AMIENS is located in PARIS (75001), in the department Paris.
The tax return of MEDICASTE AMIENS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MEDICASTE AMIENS operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.